我国首款创新型6月龄以上四价流感亚单位疫苗在济南开打

Group 1 - Influenza is a highly contagious respiratory disease caused by the influenza virus, with the World Health Organization reporting approximately 300,000 to 650,000 deaths annually due to influenza-related respiratory diseases globally, particularly affecting high-risk groups such as pregnant women, infants, the elderly, and individuals with chronic illnesses [1] - The risk of influenza activity increases with population movement and gatherings during school openings and holidays, emphasizing the importance of timely vaccination, especially for vulnerable populations like infants [1] Group 2 - The four-valent subunit influenza vaccine, developed by Jiangsu Zhonghui Yuantong Biotechnology Co., Ltd., is recognized as a preferred choice for vaccination due to its safety and efficacy, being the first of its kind in China and an advanced third-generation influenza vaccine internationally [3] - Compared to traditional split vaccines, the subunit vaccine has a higher purity by extracting and purifying only the key antigens, hemagglutinin (HA) and neuraminidase (NA), while eliminating internal proteins and impurities, thus reducing allergic risks [3] - Clinical data indicates that the subunit vaccine has superior safety, with local adverse reaction rates in infants being 54% of that of the control group split vaccine, and fever rates in children aged 3-8 being only 46% of the control group [3] - The vaccine demonstrates good immunogenicity, effectively stimulating protective antibodies, and its safety and immunogenicity results have been recognized in the "Technical Guidelines for Influenza Vaccine Prevention and Immunization (2023-2024)" [3] - The vaccine allows for a unified dosage for individuals aged 6 months and older, simplifying outpatient procedures, and employs isotonic technology and a five-faceted micro-needle to significantly reduce injection pain and bleeding rates, enhancing the vaccination experience for infants and the elderly [3]